JP2010527939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527939A5 JP2010527939A5 JP2010508671A JP2010508671A JP2010527939A5 JP 2010527939 A5 JP2010527939 A5 JP 2010527939A5 JP 2010508671 A JP2010508671 A JP 2010508671A JP 2010508671 A JP2010508671 A JP 2010508671A JP 2010527939 A5 JP2010527939 A5 JP 2010527939A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 40
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 7
- 102000046157 human CSF2 Human genes 0.000 claims 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93140207P | 2007-05-23 | 2007-05-23 | |
| AU2007902751A AU2007902751A0 (en) | 2007-05-23 | Neutralizing antibodies | |
| PCT/AU2008/000728 WO2008141391A1 (en) | 2007-05-23 | 2008-05-23 | Neutralizing antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527939A JP2010527939A (ja) | 2010-08-19 |
| JP2010527939A5 true JP2010527939A5 (enExample) | 2011-07-07 |
Family
ID=40031329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508671A Pending JP2010527939A (ja) | 2007-05-23 | 2008-05-23 | 中和抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110044996A1 (enExample) |
| EP (1) | EP2160407A4 (enExample) |
| JP (1) | JP2010527939A (enExample) |
| CN (1) | CN101687926A (enExample) |
| AU (1) | AU2008253608A1 (enExample) |
| CA (1) | CA2687791A1 (enExample) |
| WO (1) | WO2008141391A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8398972B2 (en) | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| EP2217626A4 (en) * | 2007-11-12 | 2011-06-22 | Crc For Asthma And Airways Ltd | EPITOP FOR NEUTRALIZING ANTIBODIES |
| ES2685895T3 (es) | 2008-12-22 | 2018-10-15 | The University Of Melbourne | Tratamiento del dolor |
| CA2746827C (en) * | 2008-12-22 | 2018-01-23 | The University Of Melbourne | Osteoarthritis treatment |
| WO2011153592A1 (en) * | 2010-06-10 | 2011-12-15 | Crc For Asthma And Airways Ltd | Therapeutic molecules |
| WO2012066089A1 (en) | 2010-11-18 | 2012-05-24 | Merck Serono Sa | Antibody with specificity for gm-csf (ii) |
| WO2012066071A1 (en) | 2010-11-18 | 2012-05-24 | Merck Serono S.A. | Antibody with specificity for gm-csf (i) |
| JP2014520784A (ja) | 2011-07-06 | 2014-08-25 | モルフォシス・アー・ゲー | 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| JP6490419B2 (ja) * | 2014-12-24 | 2019-03-27 | 学校法人関西医科大学 | 制御性ｔ細胞分化誘導剤 |
| US10316078B2 (en) * | 2015-03-17 | 2019-06-11 | Agency For Science, Technology And Research | Serotype cross-reactive, dengue neutralizing antibody and uses thereof |
| CA3036509C (en) | 2016-09-19 | 2022-10-25 | I-Mab | Anti-gm-csf antibodies and uses thereof |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2060741A1 (en) * | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| JP4261907B2 (ja) * | 2000-10-20 | 2009-05-13 | 中外製薬株式会社 | 低分子化アゴニスト抗体 |
| WO2003068924A2 (en) * | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| RS54127B1 (sr) * | 2005-04-18 | 2015-12-31 | Amgen Research (Munich) Gmbh | Antitela neutralizatori humanog faktora stimulacije kolonije granulocita makrofaga |
| CA2608498C (en) * | 2005-05-18 | 2017-04-04 | Morphosys Ag | Anti-gm-csf antibodies and uses therefor |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| EP2217626A4 (en) * | 2007-11-12 | 2011-06-22 | Crc For Asthma And Airways Ltd | EPITOP FOR NEUTRALIZING ANTIBODIES |
| DK2215119T3 (da) * | 2007-11-13 | 2013-02-04 | Evec Inc | Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. |
-
2008
- 2008-05-23 CN CN200880023397A patent/CN101687926A/zh active Pending
- 2008-05-23 EP EP08747994A patent/EP2160407A4/en not_active Withdrawn
- 2008-05-23 CA CA002687791A patent/CA2687791A1/en not_active Abandoned
- 2008-05-23 AU AU2008253608A patent/AU2008253608A1/en not_active Abandoned
- 2008-05-23 US US12/601,514 patent/US20110044996A1/en not_active Abandoned
- 2008-05-23 WO PCT/AU2008/000728 patent/WO2008141391A1/en not_active Ceased
- 2008-05-23 JP JP2010508671A patent/JP2010527939A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010527939A5 (enExample) | ||
| KR102597804B1 (ko) | 이중 특이적 항체 | |
| JP2010526028A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2009517057A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2017110002A5 (enExample) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| CN110582511A (zh) | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 | |
| JP2014512809A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| RU2018100820A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2015525795A5 (enExample) | ||
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| JP2013542194A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2012526542A5 (enExample) | ||
| JP2015503909A5 (enExample) |